Baird Financial Group Inc. Increases Stock Holdings in Biogen Inc. $BIIB

Key Points

• Baird Financial Group increased its Biogen holdings by 264.6% in the second quarter, bringing its position to 15,360 shares valued at approximately $3.32 million. Institutional investors collectively own 87.93% of Biogen’s outstanding stock.
• Analysts remain generally positive, with Biogen receiving a “Moderate Buy” consensus rating and an average price target of $230.14. Recent target prices range from $175 to $300.
• Biogen exceeded quarterly expectations, reporting earnings of $3.60 per share versus a $2.94 consensus estimate and revenue of $2.74 billion versus $2.46 billion expected. Revenue increased 3.4% year over year, while the company’s fiscal 2026 earnings guidance is $12.00–$13.00 per share.

Baird Financial Group Inc. boosted its holdings in Biogen Inc. (NASDAQ:BIIB - Free Report) by 264.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 15,360 shares of the biotechnology company's stock after purchasing an additional 11,147 shares during the quarter. Baird Financial Group Inc.'s holdings in Biogen were worth $3,319,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the business. Bell Investment Advisors Inc purchased a new position in shares of Biogen during the 2nd quarter worth about $27,000. Reflection Asset Management purchased a new position in Biogen during the fourth quarter worth approximately $25,000. Root Financial Partners LLC raised its stake in Biogen by 198.4% during the fourth quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company's stock worth $33,000 after purchasing an additional 123 shares during the period. MV Capital Management Inc. acquired a new position in shares of Biogen in the 4th quarter valued at $34,000. Finally, Cassaday & Co Wealth Management LLC acquired a new position in shares of Biogen in the 1st quarter valued at $40,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Royal Bank Of Canada upped their price objective on Biogen from $240.00 to $260.00 and gave the stock an "outperform" rating in a report on Tuesday, August 25th. HSBC lifted their target price on Biogen from $165.00 to $175.00 and gave the company a "reduce" rating in a report on Thursday, September 10th. TD Cowen boosted their price target on Biogen from $215.00 to $225.00 and gave the company a "buy" rating in a research report on Thursday, July 30th. Wolfe Research upgraded Biogen from a "peer perform" rating to an "outperform" rating and set a $300.00 price target for the company in a research note on Thursday, August 13th. Finally, Stifel Nicolaus set a $242.00 price objective on Biogen in a report on Thursday, September 10th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Biogen presently has an average rating of "Moderate Buy" and an average target price of $230.14.

Biogen Trading Down 0.1%

NASDAQ:BIIB opened at $216.01 on Thursday. The business's 50-day moving average is $210.27 and its two-hundred day moving average is $197.90. The firm has a market capitalization of $31.92 billion, a PE ratio of 38.23, a price-to-earnings-growth ratio of 2.39 and a beta of 0.17. Biogen Inc. has a 12 month low of $135.39 and a 12 month high of $225.80. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.87 and a quick ratio of 1.26.

Biogen (NASDAQ:BIIB - Get Free Report) last issued its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, topping the consensus estimate of $2.94 by $0.66. The company had revenue of $2.74 billion during the quarter, compared to the consensus estimate of $2.46 billion. Biogen had a return on equity of 11.18% and a net margin of 8.32%.The company's revenue was up 3.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $5.47 earnings per share. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Research analysts predict that Biogen Inc. will post 12.41 earnings per share for the current fiscal year.

Biogen Profile

Biogen Inc is a biotechnology company focused on discovering, developing and commercializing therapies for neurological and neurodegenerative diseases. Founded in 1978, the company is headquartered in Cambridge, Massachusetts, and serves patients and healthcare providers in markets around the world.

Biogen's portfolio includes treatments for multiple sclerosis, including Tecfidera, Vumerity, Tysabri, Avonex and Plegridy, as well as Spinraza for spinal muscular atrophy, developed in collaboration with Ionis Pharmaceuticals.

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.